blinatumomab
astellas,amgen
['leusm', 'blinatumomab']
#ash22 #leusm boissel: mrd+ post blin assoc with poor outcome. conclusion: in this study, inclusion of blin *in a subgroup with high risk features* (so can t be directly compared with e1910) led to 52% decrease in cumulative incidence of relapse. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)